OUR RESULTS
Incredible efficacy
Clinical studies of our innovative GL-1 formulation have revealed a sophisticated approach to managing psoriasis at its source. In laboratory testing at Munster Technological University, our steroid-free formulation demonstrated significant effectiveness in reducing key inflammatory markers, particularly IL-6, which plays a crucial role in psoriasis development. Advanced LC-QTOF analysis identified over 3,000 bioactive compounds in our formula with 85% confidence threshold, including four key compounds derived from sesame: chlorogenic acid, palmitic amide, 16-hydroxyhexadecanoic acid, and coumaric acid, all known to have anti-inflammatory and antioxidant properties."
What makes GL-1 particularly groundbreaking is its ability to interrupt the 'feed-forward' inflammatory cascade that characterises psoriasis. In this condition, inflammatory cells in the skin produce TNFα and IL-23, which trigger Th17 cells to release IL-17. This creates a self-amplifying cycle of inflammation, as IL-17 prompts skin cells to produce more inflammatory signals, drawing additional inflammatory cells to the affected areas. Our research suggests that GL-1 can help break this cycle while simultaneously combating oxidative stress in skin cells - addressing two crucial factors in psoriasis development.
These findings are especially significant because our natural formulation achieved these results without steroids, comparing favourably to traditional 1% hydrocortisone treatments. In vitro studies conducted by Centre for Applied Bioscience Research, Ireland showed our formulation matched or exceeded 1% hydrocortisone (Cortopin) across multiple parameters.
GL-1 demonstrated a superior safety profile, maintaining cell viability above 90% across all concentrations tested, while showing comparable anti-inflammatory activity in reducing IL-6 production.
By targeting both inflammation and oxidative stress pathways, GL-1 offers a comprehensive, sustainable approach to managing psoriasis symptoms while avoiding the risks associated with long-term steroid use. Our formula has undergone rigorous safety testing following OECD guidelines 439, 431, and 437, demonstrating non-irritant and non-corrosive properties with over 97% cell viability in human tissue models. This exceptional safety profile allows GL-1 to be used on sensitive areas including the face and skin folds, which are often problematic areas for traditional treatments.
For our patients, this means more than just clinical improvements - it represents a chance to effectively manage their condition long-term, helping restore both their skin health and their confidence in daily life.
Patient Testimonials
